Aflibercept in real-life for the treatment of age-related macular degeneration using a treat and extend protocol: The Armada study.

Our study demonstrated that intravitreal injections of aflibercept initiated under a standardized T&E for patients with treatment-naïve nAMD allow for significant visual improvement at 12 months, which was maintained over a 3-year follow-up period.